Format

Send to

Choose Destination
Inflamm Res. 2009 Jul;58(7):363-9. doi: 10.1007/s00011-009-0043-5. Epub 2009 May 6.

Lovastatin inhibits antigen-induced airway eosinophilia without affecting the production of inflammatory mediators in mice.

Author information

1
Department of Pharmacology, School of Pharmacy, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo 142-8501, Japan. chiba@hoshi.ac.jp

Abstract

OBJECTIVE AND DESIGN:

Statins have been proposed as a novel treatment of respiratory diseases. To determine the beneficial effects of statins on allergic bronchial asthma, the effect of systemic treatment with lovastatin on antigen-induced airway inflammation was investigated.

SUBJECTS:

Male BALB/c mice were used.

TREATMENTS:

Mice were sensitized and repeatedly challenged with ovalbumin (OA) antigen to induce asthmatic response. Animals were also treated with lovastatin (4 mg/kg/day, i.p.) once a day prior to and during the antigen inhalation period.

METHODS:

Inflammatory cell counts and levels of interleukin (IL)-4, IL-13, eotaxin, thymus and activation-regulated chemokine and leukotriene B(4) (LTB(4)) in bronchoalveolar lavage (BAL) fluids were measured.

RESULTS:

Significant increases in eosinophils and levels of the T helper 2 cytokines, chemokines and LTB(4) in BAL fluids in association with the increments of total and OA-specific immunoglobulin E (IgE) in sera were observed in the repeatedly antigen-challenged mice. The airway eosinophilia was ameliorated by lovastatin, whereas it had no significant effect on the levels of these inflammatory mediators or IgE.

CONCLUSION:

Lovastatin may be beneficial for the treatment of allergic inflammatory diseases in the airways, such as allergic bronchial asthma.

PMID:
19418204
DOI:
10.1007/s00011-009-0043-5
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center